Viking Therapeutics Shares Plunge on Mixed Trial Results for Obesity Drug

Viking Therapeutics, a biotechnology firm, faced a severe market selloff after presenting clinical data for its oral obesity treatment, VK2735. Initial enthusiasm for the drug’s potential has been sharply curtailed by investor concerns over its side effect profile, triggering a debate on its future commercial viability.

The company’s stock price cratered by more than 40% in a single session. This dramatic decline reflects deep-seated anxiety that adverse events could ultimately hinder the drug’s path to market approval and commercial success, overshadowing positive efficacy signals.

Efficacy Data Overshadowed by Tolerability Issues

Data from the Phase 2 VENTURE study revealed a dual narrative. On the efficacy front, the results were compelling: patients receiving the highest dose achieved an average weight loss of 12.2% over a 13-week treatment period. This level of efficacy had encouraged some market observers.

However, the tolerability data presented a significant challenge. A substantial 35% of participants in that high-dose cohort reported experiencing nausea and vomiting. More critically, the study saw a treatment discontinuation rate due to adverse events ranging from 28% to 38%, indicating a significant portion of patients could not tolerate the therapy.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Diverging Analyst Views on the Selloff

Some financial analysts have characterized the market’s brutal reaction as an overcorrection. They point to study details suggesting that the incidence of gastrointestinal side effects notably decreased after the initial three weeks of treatment, potentially indicating that patients may acclimate to the therapy.

Furthermore, analysts highlight that Viking Therapeutics possesses a strong financial position, with cash reserves exceeding $800 million. This robust war chest provides the company with ample resources to explore adjusted dosing regimens in subsequent Phase 3 trials to improve the drug’s tolerability.

The central question now is whether Viking can refine its protocol to mitigate side effects and restore investor confidence, or if the setback for VK2735 will prove insurmountable in the highly competitive obesity drug market.